ISRCTN12590498已完成未知

A randomised, double-blind, placebo-controlled study on the impact of Lorazepam on approach/avoidance behaviour in healthy individuals

Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)0 个研究点目标入组 60 人开始时间: 2014年12月8日最近更新: 2019年2月11日

试验速览

•1. Contraindications to benzodiazepines: dependence or former dependence, history of allergic reactions, history of hypotonia associated with benzodiazepines
•2. Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
•3. Women who are pregnant or breast feeding
•4. Intention to become pregnant during the course of the study
•5. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
•6. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
•7. Any history of psychiatric, neurological, dependence or systemic/rheumatic disease
•8. Known or suspected non-compliance, drug or alcohol abuse
•9. Inability to follow the procedures of the study, e.g. due to language problems
•10. Participation in another study with investigational drug within the 30 days preceding and during the present study
•11. Previous enrolment into the current study
•12. Members of the study team and their family members and dependents

发起方

Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)